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MyocardiumAbstract Structural changes affecting cardiomyocyte function may contribute to the pathophysi-
ological remodeling underlying cardiac function impairment. Recent reports have shown that
endogenous nitric oxide (NO) plays an important role in this process. In order to examine the role
of NO in cardiomyocyte remodeling, male rats were acclimated to room temperature (22 ± 1 C) or
cold (4 ± 1 C) and treated with 2.25% L-arginineHCl or 0.01% L-NAME (Nx-nitro-L-arginine
methyl ester)HCl for 45 days. Untreated groups served as controls. Right heart ventricles were rou-
tinely prepared for light microscopic examination. Stereological estimations of volume densities of
cardiomyocytes, surrounding blood vessels and connective tissue, as well as the morphometric mea-
surements of cardiomyocyte diameters were performed. Tissue sections were also analyzed for
structural alterations. We observed that both L-arginine and L-NAME supplementation induced
cardiomyocyte hypertrophy, regardless of ambient temperature. However, cardiomyocyte hypertro-
phy was associated with fibrosis and extra collagen deposition only in the L-NAME treated group.
Taken together, our results suggest that NO has a modulatory role in right heart ventricle remod-
eling by coordinating hypertrophy of cardiomyocytes and fibrous tissue preventing cardiac fibrosis.
 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
L-arginine is a precursor in the synthesis of numerous biologi-
cally important molecules whose signaling is limited to a great
extent by their availability, as well as by the expression and
activity of multiple enzymes involved in their metabolism
(Wu and Morris, 1998; Jobgen et al., 2006). One of the most
important biomolecules originating from L-arginine is NOntation.
2 A.A.A.A. Hmaid et al.which functions as a cell signaling molecule in mammalian
cells, controlling vital functions such as neurotransmission,
blood vessel tone, host defense and immunity (Moncada
et al., 1991). The enzyme that catalyzes NO production from
the guanidine group of L-arginine in an NADPH-dependent
reaction is nitric oxide synthase (NOS), which is present in
at least three distinct isoforms: neuronal NOS (nNOS, or
NOS1), inducible NOS (iNOS, or NOS2), and endothelial
NOS (eNOS, or NOS3). The recognition that all three iso-
forms of NOS are expressed in cardiomyocytes has raised sev-
eral intriguing questions regarding the signaling role of NO in
the heart. NO is produced from virtually all cell types compos-
ing the myocardium and regulates cardiac function through
both vascular-dependent and -independent effects. NO acts
as a negative inotrope in cardiac muscle (Brady et al., 1993),
and exerts a hypotensive effect via peripheral artery dilatation,
thus decreasing afterload, and it reduces the preload by the
dilatation of the venous system (Simko and Simko, 2000).
Besides its hemodynamic actions, however, the direct anti-
proliferative effects of NO may play an important role
(Kolpakov et al., 1995; Rossi and Colombini-Netto, 2001),
since NO seems to be an important factor in modulating
hypertrophic heart growth (Matsuoka et al., 1996; Simko
and Simko, 2000; Pereira and Mandarim-de-Lacerda, 2001;
Simko et al., 2004).
Cardiac hypertrophy refers to the process of cardiac thick-
ening and remodeling and may be due to cardiac pathology,
long-term exercise training (Pelliccia et al., 2002; Maron
et al., 2003) or chronic cold exposure (Cheng and Hauton,
2008). In pathological cardiac hypertrophy, myocardial struc-
ture is affected by two key pathological processes: cardiomy-
ocyte hypertrophy and a progressive accumulation of
connective tissue within the myocardial interstitium-
myocardial fibrosis (Diez et al., 2001; Rossi, 2001; Gonzalez
et al., 2004). The main etiological factor of pathological car-
diac hypertrophy is hypertension-induced chronic pressure
overload (Perrino et al., 2006). In contrast, during conditions
of increased hemodynamic requirements, such are during sus-
tained exercise training or during prolonged cold exposure, so-
called physiologic cardiac hypertrophy occurs (a condition
known as ‘‘athlete heart” as a result of cardiac adaptation to
long-term training). Physiologic cardiac hypertrophy is charac-
terized by preserved myocardial structure, with a normal pat-
tern of gene expression and collagen metabolism, and does not
progress to ventricular dysfunction (Rajiv et al., 2004).
Since NO is the endothelium-derived relaxing factor essen-
tial for regulating vascular tone and hemodynamics (Ignarro
et al., 1999), there has been a growing interest in L-arginine
supplementation to prevent and treat cardiovascular disorders.
Endothelial dysfunction due to impaired NO bioavailability in
the vasculature plays an important role in the development of
cardiovascular disease. Patients with chronic heart failure dis-
play signs of disturbed endothelial function in coronary arter-
ies (Richartz et al., 2001) and in the peripheral circulation
(Kubo et al., 1991). Since L-arginine availability is a rate-
limiting step for NOS (Baydoun et al., 1990; Mitchell et al.,
1990; Sessa et al., 1990) and its decreased availability results
in a decreased NO production (Xia et al., 1996), this amino
acid is widely available and publicized as having benefits in
the prevention and treatment of cardiovascular disorders
(Maxwell and Cooke, 1998; Boger and Ron, 2005) and
atherosclerosis risk factors, all of which are conditions thatPlease cite this article in press as: Hmaid, A.A.A.A. et al. Structural alterations in
Saudi Journal of Biological Sciences (2016), http://dx.doi.org/10.1016/j.sjbs.2016.01are associated with reduced NO biosynthesis (Creager et al.,
1992; Clarkson et al., 1996; Pieper et al., 1996; Adams et al.,
1997; Lerman et al., 1998). Dietary supplements containing
L-arginine are also claimed to have effects in healthy subjects
by promoting vasodilatation which improves perfusion and
delivery of nutrients and oxygen to various organs. However,
less is known about how L-arginine supplementation affects
the structure and function of pathologically unaltered hearts.
In contrast, chronic inhibition of NOS by Nx-nitro-L-
arginine methyl ester (L-NAME) is a well-established model
of experimental hypertension and cardiac hypertrophy
(Pechanova et al., 1999). The vascular effects of L-NAME have
been demonstrated to involve the removal of the tonic
vasodilator action of NO by eNOS inhibition (Griscavage
et al., 1995; Cohen et al., 1996; Vaziri and Wang, 1999) and
stimulation of the sympathetic nervous system via nNOS inhi-
bition (Chowdhary and Townend, 1999).
One of the important factors in increasing heart workload
is cold exposure. The ability of homeotherms to make the nec-
essary physiological and metabolic adaptations when subjected
to cold is important for their survival. These include increased
heat production that is fueled by increased food intake and/or
mobilization of body reserves which often results in a
decreased body weight gain, nitrogen balance, and skeletal
muscle accretion (Samuels et al., 1996; McAllister et al.,
2000). There is also an attendant increase in the size of the
heart (Heroux and Gridgeman, 1958; Hale et al., 1959;
Samuels et al., 1996) and its protein mass (McAllister et al.,
2000), which likely reflects its higher workload in support of
the increased thermogenesis. As we have already demonstrated
L-arginine-induced enhancement of thermogenic activity in
brown adipose tissue (Petrovic et al., 2005) and L-arginine-
induced intensification of antioxidative defense processes in
the skeletal muscle of cold-acclimated rats (Petrovic et al.,
2008), it is expected that L-arginine will further affect myocar-
dial load in rats acclimated to cold.
The aim of this study was to determine whether chronic
oral administration of L-arginine and L-NAME to adult male
rats (maintained at room temperature or acclimated to cold)
affected myocardial structure. Structural changes were charac-
terized by microscopic, stereological and morphometric
examinations.
2. Materials and methods
2.1. Experimental design
The experiment was approved by the Ethical Committee for
the Treatment of Experimental Animals of the Institute of Bio-
logical Research ‘‘Sinisa Stankovic”, University of Belgrade,
and the animals were cared for in accordance with the princi-
ples of the Guide to the Care and Use of Experimental Animals.
Male Mill Hill hybrid-hooded, 2-month-old rats were used.
They were divided into three main groups. The first group
received L-arginineHCl (2.25%), and the second group
received L-NAMEHCl, (0.01%), in drinking water for
45 days. The third, untreated group served as a control, and
received tap water. The animals in all three groups were fur-
ther divided into two groups – one group was kept in a cold
room at 4 ± 1 C and the other group was kept at room tem-
perature (22 ± 1 C). Each group consisted of six animals. Therat myocardium induced by chronic L-arginine and L-NAME supplementation.
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NO-induced structural alterations in rat myocardium 3animals were kept in individual cages, with food and drinking
liquids ad libitum. At the end of the experimental period the
animals were sacrificed; hearts were isolated immediately and
prepared for microscopic analyses.
2.2. Microscopic analyses
In order to obtain isotropic and uniform random sections for
stereological and morphometric studies of right ventricle, the
unbiased design-based approach to the quantitative study of
anisotropic structures – the orientator method (Mattfeldt
et al., 1990) was performed. The right ventricles were cut at
random; then placed on cut surface and again cut at random,
perpendicular to the first plane. The specimens were again
placed on the new cut surface and a new random orientation
is defined by cutting the organ in a perpendicular section to
the plane. The last cut is considered uniformly isotropic, mean-
ing that without reference to the position of the specimen in
the first cut the last surface has an orientation that varies from
all possible ones. One half of the randomly selected heart right
ventricle samples from each animal was fixed in 2.5% glu-
taraldehyde, postfixed in 1% osmium tetroxide and embedded
in Araldite (Fluka, Germany). Semi-fine serial sections were
cut using an ultramicrotome (Leica, Germany) and stained
with toluidine blue. Micrographs (magnification 100  10) of
each section were obtained for stereological and morphometric
analyses (Axio Imager M1, Carl Zeiss, Germany). The other
half of the randomly selected heart right ventricle samples
was fixed in buffered 10% formalin and embedded in paraffin.
Five-lm thick paraffin sections were cut using a microtome
(Reichert, Austria), stained with Azan trichrome and analyzed
microscopically (Axio Imager M1). Micrographs (magnifica-
tion 100  10) were obtained for histological analysis and mor-
phometric analysis of cardiomyocyte diameters.
2.3. Morphometric and stereological analyses
2.3.1. Estimations of volume densities of cardiomyocytes, blood
vessels and connective tissue in the myocardium
The volume densities of the major myocardial components
(cardiomyocytes, blood vessels and connective tissue) were
obtained using a standard point-counting technique (Weibel,
1981) and the ImageJ image analysis system (NIH, USA). This
technique allows the determination of the volume fraction of
each compartment as a ratio of the number of points falling
on the compartment relative to the total number of points fall-
ing on the myocardial tissue. An orthogonal grid with 8  10
intersections was superimposed on light micrographs at a final
magnification of 1000 (15 micrographs per animal). Volume
densities were expressed as percentage fractions of cardiac
muscle tissue.
2.3.2. Measurement of cardiomyocyte diameters
Morphometric evaluation of cardiomyocyte diameters was
performed using the ImageJ image analysis system. Measure-
ments were performed exclusively on longitudinal azan
trichrome-stained sections of myocardium. 150–260 cardiomy-
ocyte diameters per animal were analyzed in the central region
of the cell (nuclear level). Results are presented as mean value
±SEM. In order to follow the trend in cardiomyocytePlease cite this article in press as: Hmaid, A.A.A.A. et al. Structural alterations in r
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tion was constructed with a class interval of 5 lm.
2.3.3. Statistical analysis
To test data for normality, the Kolmogorov–Smirnov test was
used. Analysis of variance (ANOVA) was used for within-
group comparisons of the data. If the F test showed an overall
difference, Student’s t-test was used to evaluate the significance
of the differences in cases of parametric distribution, or Mann–
Whitney test in cases of non-parametric distribution. Statisti-
cal significance was set at p< 0.05.
3. Results
3.1. Volume densities of cardiomyocytes, blood vessels and
connective tissue in the myocardium
The results of stereological analyses of volume densities of car-
diomyocytes, blood vessels and connective tissue are shown in
Table 1. Compared with the control group acclimated to room
temperature, cold acclimation did not significantly change vol-
ume density of myocardial tissue components (cardiomy-
ocytes, blood vessels, connective tissue), although a slight
decrease in blood vessel volume density was observed.
Chronic treatment with L-arginine at room temperature did
not lead to statistically significant changes in volume densities
of myocardial tissue components, although blood vessel and
connective tissue volume densities have tended to increase.
Chronic treatment with L-arginine in cold-acclimated animals
also showed no significant changes in volume densities of tissue
components, when compared with the appropriate control.
However, when compared with L-arginine treatment at room
temperature, cardiomyocyte volume density increased, while
volume density of blood vessels decreased (Table 1).
Both chronic treatments with L-NAME, irrespective of
ambient temperature acclimation, led to increased connective
tissue volume density associated with a decrease in cardiomy-
ocyte volume density (when compared with appropriate con-
trols). L-NAME treatment in cold-acclimated animals also
decreased blood vessel volume density, when compared with
the identical treatment in room-acclimated animals.
3.2. Structural alterations in myocardium
The control and L-arginine-treated groups acclimated to room
temperature and cold, respectively, showed correct arrange-
ment of myofibrils inside cardiomyocytes with maintenance
of myocardial striation (Fig. 1A, B, D and E). A small quantity
of connective tissue with scarce collagen fibers was found
around the cardiomyocytes.
In contrast, both the room temperature- and cold-
acclimated L-NAME-treated groups (Fig. 1C and F) showed
myofibril distortion inside the cardiomyocytes with consequent
interruption of the correct myocardial striation pattern. Depo-
sition of collagen fibers around the cardiomyocytes was also
increased, leading to connective tissue growth in the myocar-
dium of L-NAME-treated rats.
With regard to the capillary supply in the myocardium,
a reduction was evident in all cold-acclimated groups
(Fig. 1D–F).at myocardium induced by chronic L-arginine and L-NAME supplementation.
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Table 1 Volume densities of cardiomyocytes (Vvcm), blood vessels (Vvbv) and connective tissue (Vvct) in the right ventricle
myocardium of experimental groups. Compared with L-arginine treatment in room temperature-acclimated animals, L-arginine
treatment in cold-acclimated animals increases cardiomyocyte volume density and decreases blood vessel volume density. L-NAME
treatment increases connective tissue volume density and decreases cardiomyocyte volume density. Values are presented as
mean ± SEM. Statistically significant differences vs. referent control: (*) p< 0.05, (**) p< 0.01, (***) p< 0.001; statistically
significant differences vs. identical treatment at room temperature: (##) p< 0.01, (###) p< 0.001.
Room temperature Cold
Control L-arginine L-NAME Control L-arginine L-NAME
Vvcm (%) 82.25 ± 1.16 79.49 ± 0.86 77.82 ± 1.15 (**) 83.81 ± 1.23 83.06 ± 1.58 (##) 78.88 ± 1.27 (**)
Vvbv (%) 10.03 ± 0.77 11.24 ± 0.71 11.13 ± 0.67 8.97 ± 0.77 7.53 ± 0.62 (###) 7.94 ± 0.68 (##)
Vvct (%) 7.73 ± 0.84 9.10 ± 0.59 11.06 ± 1.15 (*) 7.66 ± 0.79 9.82 ± 1.69 12.49 ± 0.99 (***)
Figure 1 Representative micrographs of longitudinal sections of the right ventricles myocardia from: control groups, L-arginine- and
L-NAME-treated groups acclimated to room temperature (22 ± 1 C) and cold (4 ± 1 C), respectively. No signs of pathological
alterations were observed in (A and D) control and (B and E) L-arginine-treated groups. In (C and F) both L-NAME-treated groups,
distortion of correct myofibril arrangement in cardiomyocytes is visible. Also, collagen (blue) content in the interstitium is increased in
these groups. Azan trichrome staining. Scale bars – 50 lm.
4 A.A.A.A. Hmaid et al.3.3. Cardiomyocyte diameter
Compared with the control group acclimated to room temper-
ature, increased cardiomyocyte diameter occurred in all exper-
imental groups, however, the diameters were statistically
different (p< 0.01) only after L-arginine and L-NAME treat-
ment in room temperature-acclimated animals (Table 2).
The distribution histogram of cardiomyocyte diameters
confirmed these results, and showed a shift to greater diame-
ters in all treated and cold-acclimated groups when compared
to the room temperature-acclimated control group (Fig. 2).4. Discussion
In the present work, adult male rats were treated with
L-arginine and L-NAME for 45 days, respectively, in order toPlease cite this article in press as: Hmaid, A.A.A.A. et al. Structural alterations in
Saudi Journal of Biological Sciences (2016), http://dx.doi.org/10.1016/j.sjbs.2016.01examine the possible effects of NO on myocardial structure
during room temperature- or cold-acclimation. Our results
demonstrated that cold acclimation per se does not signifi-
cantly alter the volume densities of myocardial tissue compo-
nents, but leads to a trend in cardiomyocyte hypertrophy
followed by a downward trend in capillarity.
L-Arginine treatment in room temperature-acclimated rats
led to cardiomyocyte hypertrophy which was followed by a
simultaneous increase in capillarity and interstitial connective
tissue in the myocardium, maintaining the relative ratio of tis-
sue components unaltered. Regardless of the increase in car-
diomyocyte size, no statistically significant changes of their
volume density or in blood vessels and connective tissue
occurred in the myocardium. L-Arginine treatment following
cold acclimation acts synergistically with cold by increasing
cardiomyocyte size and decreasing myocardial capillarity.
Compared to the room temperature-acclimated group treatedrat myocardium induced by chronic L-arginine and L-NAME supplementation.
.022
Table 2 Hypertrophy of cardiomyocytes after chronic L-arginine and L-NAME treatment in both room temperature-acclimated and
cold-acclimated animals. Cardiomyocyte diameters were measured in longitudinal sections at the nuclear level. Values are presented as
mean ± SEM. (**) p< 0.01 – statistically significant differences vs. referent control.
Room temperature Cold
Control L-arginine L-NAME Control L-arginine L-NAME
Cardiomyocyte diameter (lm) 16.08 ± 0.33 17.25 ± 0.30 (**) 17.29 ± 0.28 (**) 16.98 ± 0.37 17.44 ± 0.37 17.27 ± 0.25
Figure 2 Distribution of cardiomyocyte diameters according to their size. Compared with the room temperature-acclimated group, the
percentage of cardiomyocytes with diameters over 15 lm increased in all treated and cold-acclimated groups.
NO-induced structural alterations in rat myocardium 5with L-arginine, the volume density was additionally increased
and was followed by a decrease in blood vessel volume density.
This imbalance between cardiomyocyte enlargement and cap-
illary supply could be considered to be the effect of cold, since
a declining trend in myocardial capillarity was observed in all
cold-acclimated groups.
Cardiomyocyte hypertrophy (enlargement) occurs via intra-
cellular signaling pathways within these cells (Heineke and
Molkentin, 2006) and is commonly connected with cardiac
hypertrophy, which refers to cardiac thickening and remodel-
ing. This process may be due to cardiac pathology, to long-
term exercise training (Pelliccia et al., 2002; Maron et al.,
2003) or chronic cold exposure (Cheng and Hauton, 2008).
Our results demonstrated that the structural alterations
observed corresponded to physiologic cardiac hypertrophy
since we were unable to identify any pathological changes in
the myocardial structure (no signs of increased collagen depo-
sition or myofibril distortion) after chronic L-arginine treat-
ment in male rats. The observed hypertrophic effect of
chronic L-arginine supplementation on cardiomyocytes is
inconsistent with previous findings demonstrating the anti-
proliferative effects of NO in the heart (Kolpakov et al.,
1995). It should be noted that the anti-proliferative effect
of NO and therefore of L-arginine, was observed duringPlease cite this article in press as: Hmaid, A.A.A.A. et al. Structural alterations in r
Saudi Journal of Biological Sciences (2016), http://dx.doi.org/10.1016/j.sjbs.2016.01.L-arginine treatment of existing pathological myocardial
hypertrophy, a condition that is known to be associated with
reduced NO biosynthesis (Pechanova et al., 1999). Our previ-
ous studies demonstrated L-arginine-stimulated thermogenic
activation in brown adipose tissue and acceleration of cold-
induced antioxidative defense in the skeletal muscle of these
animals (Petrovic et al., 2005, 2008), suggesting that the
observed cardiomyocyte hypertrophy in L-arginine-treated
animals is an indirect consequence of increased peripheral
circulatory demands. It remains to be elucidated whether
L-arginine-induced hypertrophy of cardiomyocytes also
includes direct NO-dependent or NO-independent mechanisms.
The most prominent effect of the NOS inhibitor, L-NAME,
on rat myocardia observed in this study was fibrosis which was
demonstrated as an increase in interstitial connective tissue
volume density accompanied by increased collagen abundance
in the interstitium. This effect was followed by cardiomyocyte
hypertrophy despite a decrease in their volume density. These
alterations were observed in both the room temperature- and
the cold-acclimated L-NAME-treated groups, compared with
the appropriate controls. When compared to the room
temperature-acclimated group treated with L-NAME, identical
treatment in cold-acclimated animals additionally enhanced
interstitial fibrosis.at myocardium induced by chronic L-arginine and L-NAME supplementation.
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6 A.A.A.A. Hmaid et al.Pathological cardiac hypertrophy is characterized not only
by the growth of myocardial fibers, but also by changes in car-
diac architecture and cellular metabolism and, finally, by
myocardial dysfunction with an increased morbidity and mor-
tality. Specific genetic expression profiles, different from the
adaptive profiles involved in physiological hypertrophy, are
activated (McMullen et al., 2003). Pressure or volume overload
causes initial hypertrophy, which represents a compensatory
mechanism for maintaining cardiac function. If these stimuli
persist, structural and functional cardiac anomalies develop.
Thus, cardiac sarcomeres become bigger with abnormal pro-
teins, resulting in a bioenergetics deficit that affects their func-
tion. The cardiac muscle fibers are disorganized, and separated
by an excessive interstitial connective tissue since collagen
metabolism is changed, resulting in a decreased degradation
and an increased deposition of collagen in the extracellular
matrix (Diez et al., 1995; Rossi, 2001). In these initial phases,
collagen composition is normal with an enlarged ventricle
(Creemers and Pinto, 2011). However, with long-term myocar-
dial remodeling, there is a buildup of fibroblasts and extracel-
lular matrix proteins, causing abnormal structure and function
in the heart, resulting in the condition known as myocardial
fibrosis (Brown et al., 2005; Krenning et al., 2010) which is clo-
sely related to the amount of ventricular hypertrophy
(Creemers and Pinto, 2011). Consequently, myocardial fibrosis
causes regional myocardial dysfunction (Rajiv et al., 2004).
The mechanisms responsible for myocardial fibrosis in
hypertrophy are not fully understood. However, growth fac-
tors such as FGF-2, TGFb, and platelet-derived growth factor,
and plasma hormones such as AngII, endothelin-1 and cate-
cholamine, have been found to contribute to the regulation
of this process (Creemers and Pinto, 2011). With regard to
the effects of chronic L-NAME administration, inhibited
NOS activity in the myocardium, brain and kidney, and
induced hypertension, hypertrophy and fibrotic remodeling
of the left ventricle have been demonstrated, suggesting that
chronic L-NAME treatment could be used in a model of patho-
logical cardiac hypertrophy (Simko et al., 2005). Moreover, in
various conditions (the absence of coenzyme tetrahydro-
biopterin, BH4; L-arginine deficiency; enhanced levels of free
radicals, and the presence of different NOS inhibitors, L-
NAME) NOS reduces molecular oxygen rather than L-
arginine, resulting in the production of superoxide rather than
NO, a phenomenon known as ‘‘NOS uncoupling” (Mu¨nzel
et al., 2008). In a positive feedback manner, the activation of
superoxide source (uncoupled eNOS) may provoke the forma-
tion of superoxide and/or ONOO–, which, in turn, oxidizes
BH4 to BH3 radical, and leads to further ROS/RNS formation
(Kuzkaya et al., 2003). Consequently, scavenging of endoge-
nous NO by superoxide anions may contribute to the dimin-
ished role of NO in the regulation of cardiac hypertrophy.
Myocardial structural alterations such are fibrosis and an
increase in collagenous proteins were described after 4 weeks
of L-NAME administration (Pechanova et al., 1997, 1999),
while extensive areas of fibrosis and myocardial necrosis were
observed after 8 weeks of L-NAME administration (Moreno
et al., 1995). It should be mentioned that the dose of L-NAME
used in our study (approximately 10 mg/kg/day) was four
times lower than that in the above-mentioned experiments
(40 mg/kg/day), and is considered a low dose which was
demonstrated to have no toxic effects (Saha et al., 1996).Please cite this article in press as: Hmaid, A.A.A.A. et al. Structural alterations in
Saudi Journal of Biological Sciences (2016), http://dx.doi.org/10.1016/j.sjbs.2016.01In conclusion, chronic L-arginine supplementation induces
a low level right ventricular hypertrophy in room
temperature-acclimated rats and significantly augments ven-
tricular hypertrophy in cold-acclimated animals. This L-
arginine-induced ventricular hypertrophy could be considered
physiological, since no signs of myocardial fibrosis were
observed. In contrast, chronic treatment with L-NAME, an
inhibitor of NOSs, caused pathological right ventricular hyper-
trophy with signs of myocardial fibrosis, demonstrating the
importance of NO depletion in the development of cardiovas-
cular disease.
Acknowledgments
This work was supported by Serbian Ministry of Education,
Science and Technological Development, Grant # 173055.
Also, financial support from the Libyan Ministry of Higher
Education and Scientific Research for the first author is thank-
fully acknowledged.
References
Adams, M.R., McCredie, R., Jessup, W., Robinson, J., Sullivan, D.,
Celermajer, D.S., 1997. Oral L-arginine improves endothelium-
dependent dilatation and reduces monocyte adhesion to endothelial
cells in young men with coronary artery disease. Atherosclerosis
129, 261–269.
Baydoun, A.R., Emery, P.W., Pearson, J.D., Mann, G.E., 1990.
Substrate-dependent regulation of intracellular amino acid con-
centrations in cultured bovine aortic endothelial cells. Biochem.
Biophys. Res. Commun. 173, 940–948.
Boger, R.H., Ron, E.S., 2005. L-Arginine improves vascular function
by overcoming deleterious effects of ADMA, a novel cardiovascu-
lar risk factor. Altern. Med. Rev. 10, 14–23.
Brady, A.J., Warren, J.B., Poole-Wilson, P.A., Williams, T.J., Hard-
ing, S.E., 1993. Nitric oxide attenuates cardiac myocyte contrac-
tion. Am. J. Physiol. 265, H176–H182.
Brown, R.D., Ambler, S.K., Mitchell, M.D., Long, C.S., 2005. The
cardiac fibroblast: therapeutic target in myocardial remodeling and
failure. Annu. Rev. Pharmacol. Toxicol. 45, 657–687.
Cheng, Y., Hauton, D., 2008. Cold acclimation induces physiological
cardiac hypertrophy and increases assimilation of triacylglycerol
metabolism through lipoprotein lipase. Biochim. Biophys. Acta
1781, 618–626.
Chowdhary, S., Townend, J.N., 1999. Role of nitric oxide in the
regulation of cardiovascular autonomic control. Clin. Sci. (Lond.)
97, 5–17.
Clarkson, P., Adams, M.R., Powe, A.J., Donald, A.E., McCredie, R.,
Robinson, J., McCarthy, S.N., Keech, A., Celermajer, D.S.,
Deanfield, J.E., 1996. Oral L-arginine improves endothelium-
dependent dilation in hypercholesterolemic young adults. J. Clin.
Invest. 97, 1989–1994.
Cohen, G.A., Hobbs, A.J., Fitch, R.M., Zinner, M.J., Chaudhuri, G.,
Ignarro, L.J., 1996. Nitric oxide regulates endothelium-dependent
vasodilator responses in rabbit hindquarters vascular bed in vivo.
Am. J. Physiol. 271, H133–H139.
Creager, M.A., Gallagher, S.J., Girerd, X.J., Coleman, S.M., Dzau, V.
J., Cooke, J.P., 1992. L-Arginine improves endothelium-dependent
vasodilation in hypercholesterolemic humans. J. Clin. Invest. 90,
1248–1253.
Creemers, E.E., Pinto, Y.M., 2011. Molecular mechanisms that
control interstitial fibrosis in the pressure-overloaded heart. Car-
diovasc. Res. 89, 265–272.
Diez, J., Laviades, C., Mayor, G., Gil, M.J., Monreal, I., 1995.
Increased serum concentrations of procollagen peptides in essentialrat myocardium induced by chronic L-arginine and L-NAME supplementation.
.022
NO-induced structural alterations in rat myocardium 7hypertension. Relation to cardiac alterations. Circulation 91,
1450–1456.
Diez, J., Lopez, B., Gonzalez, A., Querejeta, R., 2001. Clinical aspects
of hypertensive myocardial fibrosis. Curr. Opin. Cardiol. 16, 328–
335.
Gonzalez, A., Lopez, B., Diez, J., 2004. Fibrosis in hypertensive heart
disease: role of the renin-angiotensin-aldosterone system. Med.
Clin. North Am. 88, 83–97.
Griscavage, J.M., Hobbs, A.J., Ignarro, L.J., 1995. Negative modu-
lation of nitric oxide synthase by nitric oxide and nitroso
compounds. Adv. Pharmacol. 34, 215–234.
Hale, H.B., Mefferd Jr., R.B., Vawter, G., Foerster, G.E.,
Criscuolo, D., 1959. Influence of long-term exposure to adverse
environments on organ weights and histology. Am. J. Physiol.
196, 520–524.
Heineke, J., Molkentin, J.D., 2006. Regulation of cardiac hypertrophy
by intracellular signalling pathways. Nat. Rev. Mol. Cell Biol. 7,
589–600.
Heroux, O., Gridgeman, N.T., 1958. The effect of cold acclimation on
the size of organs and tissues of the rat, with special reference to
modes of expression of results. Can. J. Biochem. Physiol. 36, 209–
216.
Ignarro, L.J., Cirino, G., Casini, A., Napoli, C., 1999. Nitric oxide as a
signaling molecule in the vascular system: an overview. J. Cardio-
vasc. Pharmacol. 34, 879–886.
Jobgen, W.S., Fried, S.K., Fu, W.J., Meininger, C.J., Wu, G., 2006.
Regulatory role for the arginine-nitric oxide pathway in metabo-
lism of energy substrates. J. Nutr. Biochem. 17, 571–588.
Kolpakov, V., Gordon, D., Kulik, T.J., 1995. Nitric oxide-generating
compounds inhibit total protein and collagen synthesis in cultured
vascular smooth muscle cells. Circ. Res. 76, 305–309.
Krenning, G., Zeisberg, E.M., Kalluri, R., 2010. The origin of
fibroblasts and mechanism of cardiac fibrosis. J. Cell. Physiol. 225,
631–637.
Kubo, S.H., Rector, T.S., Bank, A.J., Williams, R.E., Heifetz, S.M.,
1991. Endothelium-dependent vasodilation is attenuated in patients
with heart failure. Circulation 84, 1589–1596.
Kuzkaya, N., Weissmann, N., Harrison, D.G., Dikalov, S., 2003.
Interactions of peroxynitrite, tetrahydrobio.pterin, ascorbic acid,
and thiols: implications for uncoupling endothelial nitric-oxide
synthase. J. Biol. Chem. 278, 22546–22554.
Lerman, A., Burnett Jr., J.C., Higano, S.T., McKinley, L.J., Holmes
Jr., D.R., 1998. Long-term L-arginine supplementation improves
small-vessel coronary endothelial function in humans. Circulation
97, 2123–2128.
Maron, B.J., McKenna, W.J., Danielson, G.K., Kappenberger, L.J.,
Kuhn, H.J., Seidman, C.E., Shah, P.M., Spencer 3rd, W.H.,
Spirito, P., Ten Cate, F.J., Wigle, E.D., 2003. American College of
Cardiology/European Society of Cardiology Clinical Expert Con-
sensus Document on Hypertrophic Cardiomyopathy. A report of
the American College of Cardiology Foundation Task Force on
Clinical Expert Consensus Documents and the European Society of
Cardiology Committee for Practice Guidelines. Eur. Heart J. 24,
1965–1991.
Matsuoka, H., Nakata, M., Kohno, K., Koga, Y., Nomura, G.,
Toshima, H., Imaizumi, T., 1996. Chronic L-arginine administra-
tion attenuates cardiac hypertrophy in spontaneously hypertensive
rats. Hypertension 27, 14–18.
Mattfeldt, T., Mall, G., Gharehbaghi, H., Moller, P., 1990. Estimation
of surface area and length with the orientator. J. Microsc. 159, 301–
317.
Maxwell, A.J., Cooke, J.P., 1998. Cardiovascular effects of L-arginine.
Curr. Opin. Nephrol. Hypertens. 7, 63–70.
McAllister, T.A., Thompson, J.R., Samuels, S.E., 2000. Skeletal and
cardiac muscle protein turnover during cold acclimation in young
rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 278, R705–
R711.Please cite this article in press as: Hmaid, A.A.A.A. et al. Structural alterations in r
Saudi Journal of Biological Sciences (2016), http://dx.doi.org/10.1016/j.sjbs.2016.01.McMullen, J.R., Shioi, T., Zhang, L., Tarnavski, O., Sherwood, M.C.,
Kang, P.M., Izumo, S., 2003. Phosphoinositide 3-kinase(p110alpha)
plays a critical role for the induction of physiological, but not
pathological, cardiac hypertrophy. Proc. Natl. Acad. Sci. U.S.A.
100, 12355–12360.
Mitchell, J.A., Hecker, M., Vane, J.R., 1990. The generation of
L-arginine in endothelial cells is linked to the release of endothe-
lium-derived relaxing factor. Eur. J. Pharmacol. 176, 253–254.
Moncada, S., Palmer, R.M., Higgs, E.A., 1991. Nitric oxide: physi-
ology, pathophysiology, and pharmacology. Pharmacol. Rev. 43,
109–142.
Moreno Jr., H., Piovesan Nathan, L., Pereira Costa, S.K., Metze, K.,
Antunes, E., Zatz, R., De Nucci, G., 1995. Enalapril does not
prevent the myocardial ischemia caused by the chronic inhibition of
nitric oxide synthesis. Eur. J. Pharmacol. 287, 93–96.
Mu¨nzel, T., Sinning, C., Post, F., Warnholtz, A., Schulz, E., 2008.
Pathophysiology, diagnosis and prognostic implications of
endothelial dysfunction. Ann. Med. 40, 180–196.
Pechanova, O., Bernatova, I., Pelouch, V., Babal, P., 1999. L-NAME-
induced protein remodeling and fibrosis in the rat heart. Physiol.
Res. 48, 353–362.
Pechanova, O., Bernatova, I., Pelouch, V., Simko, F., 1997. Protein
remodelling of the heart in NO-deficient hypertension: the effect of
captopril. J. Mol. Cell. Cardiol. 29, 3365–3374.
Pelliccia, A., Maron, B.J., De Luca, R., Di Paolo, F.M., Spataro, A.,
Culasso, F., 2002. Remodeling of left ventricular hypertrophy in
elite athletes after long-term deconditioning. Circulation 105, 944–
949.
Pereira, L.M., Mandarim-de-Lacerda, C.A., 2001. Stereology of
cardiac hypertrophy induced by NO blockade in rats treated with
enalapril and verapamil. Anal. Quant. Cytol. Histol. 23, 330–338.
Perrino, C., Naga Prasad, S.V., Mao, L., Noma, T., Yan, Z., Kim, H.
S., Smithies, O., Rockman, H.A., 2006. Intermittent pressure
overload triggers hypertrophy-independent cardiac dysfunction
and vascular rarefaction. J. Clin. Invest. 116, 1547–1560.
Petrovic, V., Buzadzic, B., Korac, A., Vasilijevic, A., Jankovic, A.,
Micunovic, K., Korac, B., 2008. Antioxidative defence alterations
in skeletal muscle during prolonged acclimation to cold: role of L-
arginine/NO-producing pathway. J. Exp. Biol. 211, 114–120.
Petrovic, V., Korac, A., Buzadzic, B., Korac, B., 2005. The effects of L-
arginine and L-NAME supplementation on redox-regulation and
thermogenesis in interscapular brown adipose tissue. J. Exp. Biol.
208, 4263–4271.
Pieper, G.M., Siebeneich, W., Dondlinger, L.A., 1996. Short-term oral
administration of L-arginine reverses defective endothelium-depen-
dent relaxation and cGMP generation in diabetes. Eur. J.
Pharmacol. 317, 317–320.
Rajiv, C., Vinereanu, D., Fraser, A.G., 2004. Tissue Doppler imaging
for the evaluation of patients with hypertrophic cardiomyopathy.
Curr. Opin. Cardiol. 19, 430–436.
Richartz, B.M., Werner, G.S., Ferrari, M., Figulla, H.R., 2001.
Reversibility of coronary endothelial vasomotor dysfunction in
idiopathic dilated cardiomyopathy: acute effects of vitamin C. Am.
J. Cardiol. 88, 1001–1005.
Rossi, M.A., 2001. Connective tissue skeleton in the normal left
ventricle and in hypertensive left ventricular hypertrophy and
chronic chagasic myocarditis. Med. Sci. Monit. 7, 820–832.
Rossi, M.A., Colombini-Netto, M., 2001. Chronic inhibition of NO
synthesis per se promotes structural intimal remodeling of the rat
aorta. J. Hypertens. 19, 1567–1579.
Saha, S.K., Ohinata, H., Kuroshima, A., 1996. Effects of acute and
chronic inhibition of nitric oxide synthase on brown adipose tissue
thermogenesis. Jpn. J. Physiol. 46, 375–382.
Samuels, S.E., Thompson, J.R., Christopherson, R.J., 1996. Skeletal
and cardiac muscle protein turnover during short-term cold
exposure and rewarming in young rats. Am. J. Physiol. 270,
R1231–R1239.at myocardium induced by chronic L-arginine and L-NAME supplementation.
022
8 A.A.A.A. Hmaid et al.Sessa, W.C., Hecker, M., Mitchell, J.A., Vane, J.R., 1990. The
metabolism of L-arginine and its significance for the biosynthesis of
endothelium-derived relaxing factor: L-glutamine inhibits the
generation of L-arginine by cultured endothelial cells. Proc. Natl.
Acad. Sci. U.S.A. 87, 8607–8611.
Simko, F., Luptak, I., Matuskova, J., Krajcirovicova, K., Sumbalova,
Z., Kucharska, J., Gvozdjakova, A., Simko, J., Babal, P.,
Pechanova, O., Bernatova, I., 2005. L-Arginine fails to protect
against myocardial remodelling in L-NAME-induced hypertension.
Eur. J. Clin. Invest. 35, 362–368.
Simko, F., Matuskova, J., Luptak, I., Krajcirovicova, K., Kucharska,
J., Gvozdjakova, A., Babal, P., Pechanova, O., 2004. Effect
of simvastatin on remodeling of the left ventricle and aorta in
L-NAME-induced hypertension. Life Sci. 74, 1211–1224.Please cite this article in press as: Hmaid, A.A.A.A. et al. Structural alterations in
Saudi Journal of Biological Sciences (2016), http://dx.doi.org/10.1016/j.sjbs.2016.01Simko, F., Simko, J., 2000. The potential role of nitric oxide in the
hypertrophic growth of the left ventricle. Physiol. Res. 49, 37–46.
Vaziri, N.D., Wang, X.Q., 1999. CGMP-mediated negative-feedback
regulation of endothelial nitric oxide synthase expression by nitric
oxide. Hypertension 34, 1237–1241.
Weibel, E.R., 1981. Stereological Methods. Vol. 1. Practical Methods
for Biological Morphometry. J. Microsc. 121, 131–132.
Wu, G., Morris Jr., S.M., 1998. Arginine metabolism: nitric oxide and
beyond. Biochem. J. 336 (Pt 1), 1–17.
Xia, Y., Dawson, V.L., Dawson, T.M., Snyder, S.H., Zweier, J.L.,
1996. Nitric oxide synthase generates superoxide and nitric oxide in
arginine-depleted cells leading to peroxynitrite-mediated cellular
injury. Proc. Natl. Acad. Sci. U.S.A. 93, 6770–6774.rat myocardium induced by chronic L-arginine and L-NAME supplementation.
.022
